Search clinical trials for: MEDI-534, Cohort 4

Total 171 results

MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Healthy

United States, Australia, Spain, Germany, Canada, Finland, South Africa, Brazil, Israel
MedImmune LLC

Completed

Study to Evaluate MEDI-534 in Healthy Adults

Respiratory Syncytial Virus Infections | Parainfluenza Infections

United States
MedImmune LLC

Completed

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (CP149)

Respiratory Syncytial Virus Infections | Respiratory Viral Infections | Parainfluenza Virus 3, Human

United States
MedImmune LLC

Completed

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Healthy

United States
Wuhan YZY Biopharma Co., Ltd.

Not yet recruiting

A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

HER2-Positive Solid Tumors
MedImmune LLC

Withdrawn

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

Wheezing
XOMA (US) LLC

Completed

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United Kingdom, United States
MedImmune LLC

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Respiratory Syncytial Virus Infections

United States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...
MedImmune LLC

Completed

Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

Respiratory Syncytial Virus Infections

Chile, Argentina
MedImmune LLC

Completed

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

Healthy

United States
MedImmune LLC

Terminated

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Participants Less Than 12 Months of Age With RSV Illness

United States
Emergent BioSolutions

Completed

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Typhoid

United States
MedImmune LLC

Completed

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

Respiratory Syncytial Virus Prophylaxis
MedImmune LLC

Completed

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
Alopexx Vaccine, LLC

Completed

A Study of AV0328 Administered to Healthy Adult Volunteers

PNAG-expressing Pathogenic Microbes Vaccine

United States
MedImmune LLC

Completed

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

RSV Illness in ≤12 Months of Participants

United States, Chile, New Zealand, Australia, Panama
Kangabio AUSTRALIA LTD PTY

Not yet recruiting

A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Brown University
GlaxoSmithKline

Completed

A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema (BrUOG-PA205)

Metastatic Pancreatic Cancer

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

France, Germany
Nuvamid SA
Medpace, Inc.; Anapharm; LGD

Active, not recruiting

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Healthy Volunteers

United States
Rezolute

Completed

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, Denmark, United Kingdom, Russian Federation, Spain, Bulgaria, Canada, Georgia, Germany, Israel, Turkey
MedImmune LLC

Withdrawn

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia
MedImmune LLC

Withdrawn

A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin
Arthrosi Therapeutics

Completed

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

Healthy Volunteers

Australia
Cougar Biotechnology, Inc.

Completed

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (mCRPC)

Prostate Cancer | Prostate Neoplasms

United States
Wuhan YZY Biopharma Co., Ltd.

Active, not recruiting

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

Metastatic or Locally Advanced Solid Tumors

China
Wuhan YZY Biopharma Co., Ltd.

Unknown

A Study of M701 (EpCAM and CD3) in Malignant Ascites

Cancer | Malignant Ascites

China
AmtixBio Co., Ltd.

Not yet recruiting

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Onychomycosis

New Zealand
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Intron Biotechnology, Inc.

Completed

A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

Acute Radiation Syndrome

Korea, Republic of
MedImmune LLC

Completed

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Congenital Heart Disease

United States, Spain, United Kingdom, Canada, Belgium, Germany, Israel, Austria, Poland, Russian Federation, Sweden, Lebanon, France, Czech Republic, Hungary, Denmark, Bulgaria
AO GENERIUM

Recruiting

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

ALL | B-precursor Acute Lymphoblastic Leukemia | GNR-084

Russian Federation
Institut Straumann AG

Active, not recruiting

4 mm Implants in Fixed Cross-Arch Prostheses

Jaw Edentulous

Switzerland, United Kingdom
Centre hospitalier de l'Université de Montréal...
Université de Montréal

Completed

Online Perceptual Modules and Spaced Learning, a Modern Approach to Teaching LVEF Assessment to Medical Students. (MAP-ETT)

Medical Education

Canada
Jeil Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

Anti-Ulcer Agents

Korea, Republic of
Chinese PLA General Hospital

Unknown

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

China
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Natural History of HPV Infection in Men: The HIM Study

Human Papillomavirus

United States
Arthrosi Therapeutics

Completed

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

Healthy Volunteers

Australia
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Motavizumab Administration for a Second Season for RSV Prophylaxis

Chile, Brazil
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
Pfizer
Halozyme Therapeutics

Terminated

Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Healthy | Hypercholesterolemia

Belgium
Pfizer

Completed

First Safety Study in Humans of a Single Dose of CPG 52364

Healthy Volunteers

United States
Universität Duisburg-Essen
University of Witten/Herdecke

Completed

Lifestyle Modification Program for Patients With Chronic Pain Conditions (POSITAG)

Chronic Pain

Germany
Sara Zayed

Active, not recruiting

Treatment Outcome of Short Implant Assisted Mandibular Overdenture

Atrophy of Edentulous Mandibular Alveolar Ridge

Egypt
Fujian Medical University Union Hospital

Recruiting

Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer

Rectal Cancer | Radiation Oncology

China
New Mexico Cancer Care Alliance

Completed

Combination Paclitaxel, Carboplatin and Temozolomide

Lung Diseases | Cancer

United States
New Mexico Cancer Care Alliance

Completed

Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies

Lung Cancer

United States
Ikena Oncology
Gilead Sciences

Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid Tumor

United States
Pfizer

Completed

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Neoplasms

Poland, United States, Spain

3

Subscribe